ÂÜÀòÂÒÂ×

Maryam Jangani is a highly experienced Principal Scientist currently with Adaptimmune since February 2021, focusing on the development, qualification, and validation of immunological assays within ICH guidelines for GMP environments. Prior to this role, Maryam served as a Principal Researcher at Eisai EMEA, investigating antibody-mediated interactions with Tau fibrils using advanced imaging techniques. Additional experience includes a position as Senior Scientist at Horizon Discovery, where Maryam specialized in CRISPR editing in primary immune cells, and a Postdoctoral Research Fellow role at Queen Mary University of London, researching mTORC2-dependent metabolic regulation in myeloid cells. Maryam also has a postdoctoral background from Barts Cancer Institute and holds a PhD in Molecular Medicine from The University of Manchester, complemented by an MRes and a BSc in relevant biomedical fields from the University of Liverpool and The University of Manchester respectively.